Purine analogues as kinase inhibitors: A review

Recent Patents on Anti-Cancer Drug Discovery

Volumn 10, Issue 3, 2015, Pages 308-341

  Sharma, Sahil ^a   Mehndiratta, Samir ^b   Kumar, Sunil ^b   Singh, Jagjeet ^c   Bedi, Preet M S ^a   Nepali, Kunal ^b  

^a GURU NANAK DEV UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

^c Rayat Bahra Institute of Pharmacy   (India)

Author keywords

Chemotherapy; Clinical trials; Patents; Potential inhibitors; Protein kinases; Purines

Indexed keywords

ACICLOVIR; MERCAPTOPURINE; PENCICLOVIR; PENTOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PURINE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; BINDING ASSAY; CANCER INHIBITION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION ASSAY; CHEMICAL STRUCTURE; HUMAN; IC50; LEUKEMIA; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA; PROTEIN KINASE INHIBITORS; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84947740920     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892810666150617112230     Document Type: Review

References (87)

1. [1] Nepali K, Sharma S, Sharma S, Bedi PMS, Dhar KL. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anti-cancer hybrids. Eur Med Chem 2014; 77: 422-87.
2. [2] Nepali K, Kadian K, Ojha R, Dhiman R, Garg A, Singh G, et al. Effect of ring A and ring B substitution on the cytotoxic potential of pyrazole tethered chalcones. Med Chem Res 2012; 21: 2990-7.
3. [3] Singh J, Sharma S, Saxena AK, Nepali K, Bedi PMS. Synthesis of 1, 2, 3-triazole tethered bifunctional hybrids by click chemistry and their cytotoxic studies. Med Chem Res 2013; 22: 3160-9.
4. [4] Sharma M, Sharma S, Buddhiraja A, Saxena AK, Nepali K, Bedi PMS. Synthesis and cytotoxicity studies of 3, 5-diaryl N-acetyl pyrazoline-isatin hybrids. Med Chem Res 2014; 23(10): 4337-44.
5. [5] Sharma S, Kaur C, Budhiraja A, Nepali K, Gupta MK, Saxena AK, et al. Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modeling Studies. Eur Med Chem 2014; 85: 648-60.
6. [6] Sweety SK, Nepali K, Sapra S, Suri OP, Dhar KL, Sarma GS, et al. Synthesis and biological evaluation of chalcones having heterosubstituent (s). Ind Pharm Sci 2010; 72 (6): 801-6.
7. [7] Budhiraja A, Kadian K, Kaur M, Aggarwal V, Garg A, Sapra S, et al. Synthesis and biological evaluation of naphthalene, furan and pyrrole based chalcones as cytotoxic and antimicrobial agents. Med Chem Res 2012; 21: 2133-40.
8. [8] Nepali K, Sharma S, Kumar D, Budhiraja A, Dhar KL. Anti-cancer hybrids-a patent survey. Rec Pat Anti-Can Drug Disc 2014; 9(3): 303-39.
9. [9] Kaur R, Kaur P, Sharma S, Singh G, Mehndiratta S, Nepali K. Anti-cancer pyrimidines in diverse scaffolds: A review of patent literature. Recent Pat Anti-cancer Drug Disco 2015; 10(1): 23-71.
10. [10] Mangla V, Nepali K, Singh G, Singh J, Guru S, Gupta MK, et al. Structure activity relationship of arylidene pyrrolo and pyrido [2,1-b] quinazolones as cytotoxic agents: synthesis, SAR studies, bio- logical evaluation and docking studies. Med Chem 2013; 9(5): 642-50.
11. [11] Kumar D, Nepali K, Bedi PMS, Kumar S, Malik F, Jain S. 4, 6-Diaryl pyrimidones as constrained chalcone analogues: Design, synthesis and evaluation as antiproliferative agents. Antican Agents Med Chem 2015; [Epub ahead of print].
12. [12] Nepali K, Ojha R, Sharma S, Bedi PMS, Dhar KL. Tubulin inhibitors: A patent survey. Rec Pat Anti-Can Drug Disc 2014; 9: 176-220.
13. [13] Kumar S, Mehndiratta S, Nepali K, Gupta MK, Koul S, Sharma PR, et al. Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors. Org Med Chem Lett 2013; 1: 13.
14. [14] Tuccinardi T, Martinelli A. Protein kinase homology models: Recent developments and results. Curr Med Chem 2011; 18: 2848-53.
15. [15] Rosemeyer H. The chemodiversity of purine as a constituent of natural products. Chem Biodivers 2004; 1: 361.
16. [16] Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. Screening for hypersensitivity to abacavir. New Eng J Med 2008; 358: 568-79.
17. [17] Rossi S. Australian Medicines Handbook. 3rd ed. Adelaide: Australian Medicines Handbook 2006.
18. [18] Thackray AM, Field HJ. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J Infect Dis 1996; 173: 291-9.
19. [19] Kijjoa A, Sawangwong P. Drugs and Cosmetics from the Sea. Mar Drugs 2004; 2: 73-82.
20. [20] de Clercq Erik, Field HJ. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 2006; 147: 1-11.
21. [21] Choudary BM, Geen GR, Kincey PM, Parratt MJ, Robert J, Dales M, et al. A direct approach to the synthesis of famciclovir and penciclovir nucleos and nucleot 1996; 15: 981.
22. [22] Sneader W. Drug Discovery: A History. A John Wiley & Sons, Inc., Publication: New York 2005.
23. [23] Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
24. [24] Vora A, Mitchell CD, Lennard L, Edon TO, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6- mercaptopurine in childhood lymphoblastic leukaemia: A randomised trial. Lancet 2006; 368: 1339-48.
25. [25] Rogowski M, Chodynicki S. Use of the preparation Cafaminol in the treatment of acute rhinitis. Wiad Lek 1985; 38: 1437-40.
26. [26] Sherer JT, Glover PH. Pentoxifylline for sickle-cell disease. Ann Pharmacother 2000; 34: 1070-4.
27. [27] Schultze-Werninghaus G, Meier-Sydow J. The clinical and pharmacological history of theophylline: First report on the bron- chospasmolytic action in man by Hirsch SR. in Frankfurt (Main) 1922. Clin Allergy 1922; 12: 211-15.
28. [28] Mader TJ, Gibson P. Adenosine receptor antagonism in refractory asystolic cardiac arrest: Results of a human pilot study. Resuscitation 1997; 35: 3-7.
29. [29] Maltzman JS, Koretzky GA. Azathioprine: Old drug, new actions. J Clin Invest 2003; 111: 1122-1124.
30. [30] Uramoto M, Kim CJ, Kazuo SY, Kusakabe H, Isono K, Phillips DR, et al. Isolation and characterization of phosmidosine. A new antifungal nucleotide antibiotic. J Antibiot 1991; 44: 375.
31. [31] Rosenmeyer H. The chemodiversity of purine as a constituent of natural products. Chem Biodivers 2004; 1(3): 361-401.
32. [32] Nakamura H, Wu H, Ohizumi Y, Hirata Y. Agelasine-A, -B, -C and -D, novel bicyclic diterpenoids with a 9-methyladeninium unit possessing inhibitory effects on na,K-atpase from the okinawa sea sponge Agelas sp.1. Tet Lett 1984; 25(28): 2989-92.
33. [33] Wu H, Nakamura H, Kobayashi J, Ohizumi Y. Agelasine-E and -F, novel monocyclic diterpenoids with 9-methyladeninium unit possessing inhibitory effects on Na,K-ATPase isolated from the Okinawan sea sponge Agelas nakamurai. HoshinoLett 1984; 25(34): 3719-22.
34. [34] Ishida K, Ishibashi M, Shigemori H, Sasaki T, Kobayashi J. Agela-sine G. A new antileukemic alkaloid from the Okinawan marine sponge Agelas sp. Chem Pharm Bull 1992; 40: 766-7.
35. [35] Fu X, Schmitz FJ, Tanner RS, Kelly-Borges H. Agelasines H and I, 9-methyladenine-containing diterpenoids from an Agelas sponge. J Nat Prod 1998; 61: 548-50.
36. [36] Prestwich SA, Bolton TB. Inhibition of muscarinic receptor-induced inositol phospholipid hydrolysis by caffeine, beta- adrenoceptors and protein kinase C in intestinal smooth muscle. Br J Pharmacol 1995; 114: 602-11.
37. [37] Huang S, Qu LK, Cuddihy AR, Ragheb R, Taya Y, Koromilas AE. Protein kinase inhibitor 2-aminopurine overrides multiple genotoxic stress-induced cellular pathways to promote cell survival. http://www.ncbi.nlm.nih.gov/pubmed/12802279 Oncogene 2003; 22: 3721-33.
38. [38] Bhaumik D, Datta AK. Active site thiol(s) in Leishmania donovani adenosine kinase: Comparison with hamster enzyme and evidence for the absence of regulatory adenosine binding site. Mol Biochem Parasitol 1992; 52: 29-38.
39. [39] Mackowiak M, Kolasiewicz W, Markowicz-Kula K, Wedzony K. Purvalanol A, inhibitor of cyclin-dependent kinases attenuates proliferation of cells in the dentate gyrus of the adult rat hippocampus. Pharmacol Rep 2005; 57: 845-9.
40. [40] Sheryanna AM, Smith J, Bhangal G, Barnett A, McClue S, Tam FW, et al. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis. Nephrology 2011; 16: 4106.
41. [41] Wong C, Griffin RJ, Hardcastle IR, Northen JS, Wang LZ, Golding BT. Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated SN2 reactivity of 2, 2, 2-trifluoroethoxysulfonates. Org Biomol Chem 2010; 8: 2457-64.
42. [42] Bibian M, Ronald JR, Jun YC, Yoshihiko N, Stephan S, Weimin C, et al. Development of highly selective casein kinase 1 /1 (CK1 /) inhibitors with potent antiproliferative properties. Bioorg Med Chem Lett 2013; 23: 4374-80.
43. [43] Gilbert AM, Pawel N, Natasja B, Matthew GB, Christoph D, Efren DS, et al. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-: Hit to lead studies. Bioorg Med Chem Lett 2010; 20: 636-39.
44. [44] Venkatesan AM, Christoph MD, Zecheng C, Efren DS, Osvaldo DS, Matthew B, et al. Novel imidazolopyrimidines as dual PI3- Kinase/mTOR inhibitors. Bioorg Med Chem Lett 2010; 20: 653-56.
45. [45] Shahani VM, Ball DP, Ramos AV, Li Z, Paul AS, Haftchenary S, et al. A 2, 6, 9-hetero- trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. Bioorg Med Chem 2013; 21: 5618-28.
46. [46] Yang J, Wang LJ, Liu JJ, Zhong L, Zheng RL, Xu Y, et al. Structural optimization and structure-activity relationships of N2-(4-(4-ethylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations. J Med Chem 2012; 55: 10685-99.
47. [47] Zatloukal M, Radek J, Tomas G, Eva R, Jiri V, Tomas P, et al. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases. Eur J Med Chem 2013; 61: 61-72.
48. [48] Paulson A, Stephanie B, Chang KS, Chaiping L, Meredith W, Haishan W, et al. Structure-based design of PDK1 inhibitors. Bioorg Med Chem Lett 2012; 22: 305-7.
49. [49] Kim D, Hyunseung L, Hwiseok J, Soon-Sun H, Sungwoo H. Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution. Bioorg Med Chem 2011; 19: 2508-16.
50. [50] Kumar V, Christophe H, Matthew B, Paul S, David G, Kraig Y, et al. Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. Bioorg Med Chem Lett 2012; 22: 4377-85.
51. [51] Chen, D., Williams, M. Pyrimidine substituted purine compounds as kinase(s) inhibitors. US20150105383 (2015).
52. [52] Nagaraj, H.K.M., Williams, M. Pyrimidine substituted purine derivatives. US20140066620 (2014).
53. [53] Nagaraj, H.K.M., Williams, M. Pyrimidine substituted purine derivatives. US20130079512 (2013) & AU2013251254 (2013).
54. [54] Nagaraj, H.K.M., Williams, M. Pyrimidine substituted purine derivatives. US20100298319 (2010).
55. [55] Fowwler, K.W., Huang, D., Kesicki, E.A., OOI, H.C., Oliver, A., Ruan, F., Treiberg, J. Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta. US20130116266 (2013).
56. [56] Zatloukal, M., Krystof, V., Havlicek, L., Popa, I., Dolezal, K., Strand, M., Jorda, R. Substituted 6-(2-hydroxybenzylamino) purine derivatives, their use as medicaments and compositions containing these derivative. US20120070512 (2012).
57. [57] Castanedo, G., Chuckowree, I., Folks, A., Sutherlin, D.P., Wan, N.C. Purine PI3K inhibitor compounds and methods of use. US20120135988 (2012) & US20090318411 (2009).
58. [58] Nagaraj, H.K.M., Chen, D., Poulsen, A., Williams, M. 2-Morpholinylpurines as inhibitors of PI3K. US20110009403 (2011).
59. [59] Mortensen, M.D.S., Delgado, M.M.M., Joseph, J.S., Albers, R.J., Lee, B.G, Huang, D., Schwarz, K.L., Parnes, J.S., Riggs, J.R., Papa, P.W. Heteroaryl compounds, compositions thereof, use thereof as protein kinase inhibitors. NZ20070576279 (2011).
60. [60] Ling, C., Li, Z. PI3K Isoform selective inhibitor. US20110130398 (2011).
61. [61] Goldsmith, P., Hancox, T.C., Pegg, N.A., Kulagowski, J.J., Nadin, A.J., Price, S. Purine derivatives useful as PI3 kinase inhibitor. US20110230464 (2011).
62. [62] Chen, D., Nagaraj, M.H.K., William, M. 8-Substituted-2-morpholino purines for as PI3K and/or mTOR inhibitors in the treatment of proliferative disorders. WO2010114494 (2010).
63. [63] Ding, P., Argade, A., Golff, D., Singh, R., Masuda, E., Taylor, V., Masuda, E., Taylor, V., Holland, S. Kinase inhibitors and their uses. US20070142402 (2007) & US20100069369 (2010).
64. [64] Zask, A., Dehnhardt, C.M., Kaplan, J.A., Santos, E.G.D., Venkate-san, A.M., Verheijen, J.C. 1H-pyrazolo[3,4-D]pyrimidine,purine, 7H-purin-8(9)-one,3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3K kinase inhibitors and their synthesis. US20090192176 (2009).
65. [65] Song, Y., Xu, Q., Bauer, S.W., Jia, Z.J., Mehrotra, M., Pandey, A. Inhibitor of protein kinase. WO2009131687 (2009) & US20090298823 (2009).
66. [66] Hoelzemann, G., Crassier, H., Wilfried, R., Jonezyk, A. Purine derivatives as inhibitors of receptor tyrosine kinase activity. US20080214582 (2008).
67. [67] Buzzetti, F., Brasca, G.M., Longo, A., Ballinari, D. Aryl and Het-eroaryl purine compounds. CA20052209598 (2005).
68. [68] Baenteli, R., Patrick, C., Collongwood, P.S., Pascal, F., Meier, P., Schoepfer, J. Use of 9H-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9H-purine-2,6-diamine derivatives. WO2005097135 (2005).
69. [69] Collingwood, S.P., Hayler, J., le Grand, D.M., Mattes, H., Menear, K.A., Walker, C.V., Cockcroft, X.-L. Purine derivatives inhibitors of tyrosine protein kinase syk. US20036589950 (2003).
70. [70] Winzeler, E., Gray, N.S., Han, D., Cheng, D. Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases. US201000564994 (2010).
71. [71] Stadtmueller, H., Boehmelt, G., Engelhardt, H., Hirt, U., Schaaf, O., Waizenegger, I. Compounds. US20100311721 (2010).
72. [72] Berdini, V., Boyle, R.G., Saxty, G., Walker, D.W., Woodhead, S.J., Wyaat, P.G., Donald, A., Caldwell, J., Collins, I., Da Fonseca, T.F. Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinase inhibitors. US20090247538 (2009).
73. [73] Wu, H., Zhejiang Z. N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof. EP20081897882 (2008).
74. [74] Bordon-Pallier, F., Haesslein, J.-L. Novel purine derivatives, preparation method and use as medicines. US20040063732 (2004) & US20080090849 (2008).
75. [75] Stadtmueller, H., Boehmelt, G., Engelhardt, H., Hirt, U., Schaaf, O., Waizenegger, I. 9H-purine derivatives and their use in the treat- ment of proliferative diseases. WO2008107444 (2008).
76. [76] Musacchio, A. Use and compositions of purine derivatives for the treatment of proliferative disorders. WO2008135232 (2008).
77. [77] Lum, R.T., Blum, C.Y., Mackman, R., Wick, M.M., Schow, S.R., Purine inhibitors of cyclin dependent kinase 2 and IkappaBalpha. US20050080261 (2005) & US20020032327 (2002).
78. [78] Chen, S., Ding, S., Schultz, P.G. Composition and methods for inducing cell dedifferentiation. WO2005047524 (2005).
79. [79] Zablocki, J.A., Schow, S.R., Wick, M.M., Richard, M., Lynn, B.C., Lum, R.T., Ibrahim, P. Purine inhibitors of cyclin dependent kinase 2 and I-B. AU2004200192 (2004).
80. [80] Gray, N.S., Schultz, P., Wodicka, L., Meijer, L., Lockhart, D.J. Methods of using chemical libraries to search for new kinase in-hibitors. US6573044 (2003).
81. [81] Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, et al. PI3K inhibitor, GS-1101 (CAL-101), attenuates path- way signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012; 119(8): 1897-900.
82. [82] VS-5584. Available at: http://www.verastem.com/products/VS-5584.aspx. (Accessed on: April 9, 2015).
83. [83] Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yeng R. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activat- ing and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 2012; 11: 952-62.
84. [84] Berezowska S, Diermeier-Daucher S, Brockhoff G, Busch R, Duyster J, Grosu AL, et al. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells. Int J Mol Med 2010; 5: 713-21.
85. [85] BIIB021. Available at: http://www.medchemexpress.com/BIIB021.html. (Accessed on: April 9, 2015).
86. [86] Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-, Inhibitor, Shows Activity in Patients with Relapsed/Refractory T-Cell Lymphoma. Available at: https://ash.confex.com/ash/2014/webprogram/ Paper75057.html. (Accessed on: April 9, 2015).
87. [87] Johnson N, Bentley J, Wang LZ, Newell DR, Robson CN, Shapiro GI, et al. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells. Br J Cancer 2010; 102(2): 342-50.